alexa Perfect Chemotherapy of Uterine Malignancy Followed by Normal Pregnancy | OMICS International
ISSN: 2157-7420
Journal of Health & Medical Informatics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Perfect Chemotherapy of Uterine Malignancy Followed by Normal Pregnancy

Kazuo Maeda*

Department of Obstetrics and Gynecology (Emeritus), Tottori University Medical School, Yonago, Japan

*Corresponding Author:
Kazuo Maeda
Department of Obstetrics and Gynecology (Emeritus)
Tottori University Medical School, Yonago, Japan
3-125, Nadamachi, Yonago, Tottoriken, 6830835, Japan
Tel: 81-859-22-6856
Fax: 81-859-22-6856
E-mail: [email protected]

Received Date: November 22, 2013; Accepted Date: November 23, 2013; Published Date: November 28, 2013

Citation: Maeda K (2013) Perfect Chemotherapy of Uterine Malignancy Followed by Normal Pregnancy. J Health Med Informat. 5:e118. doi: 10.4172/2157-7420.1000e118

Copyright: © 2013 Maeda K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Health & Medical Informatics

The choriocarcinoma is a uterine malignant neolasia characterized by postmolar development accompanied with general metastases, and the patient died by brain hemorrhage of brain metastasis within 2 years after the total hysterectomy in old times. The author was enthusiastic to treat the malignancy as a systemic disease instead of a local malignancy within the uterus with MTX chemotherapy in 1960s, to which vhoriocarcinoma was highly sensitive and even brain metastasis disappeared by the complete remission after MTX chemotherapy. Invasive mole was another trophoblastictumor localized in the myometrium but its sensitivity to MTX was lower than choriocarcinoma, because the molar tissue was more highly differentiated than choriocarcinoma. A surgery was the most effective in the invasive mole, where it was ultrasonically diagnosed by its villous structure in the myometrium.Since the primary choriocarcinoma focus was usually located in the uterus, it was treated by MTX chemotherapy prior to hysterectomy at the same time with the distant metastasis. That was the primary chemotherapy, which preserved uterus, promising future pregnancy and child birth, if the primary focuses disappeared by the MTX chemotherapy. Some choriocarcinoma patients received the primary chemotherapy followed by the recovery of fertility and normal pregnancy. The MTX chemotherapy of choriocarcinoma was provided usually by intensive regimen, where 0.4-0.5 mg/kg MTX was injected intramuscularly or by drip infusion for 3-4 days in a week, followed by 3-6 mg Leucovorin after MTX administration. Actinomycin-D was usually combined with MTX. The chemotherapy was monitored by the HCG in the blood or urine, where the chemotherapy course was repeated every week until the disappearance of HCG [1]. Another monitor to detect choriocarcinoma sensitivity was the ultrasonic pulsed Doppler peripheral blood floe resistance of the tumor mass, i.e. resistance index and pulsatility index of tumor vascular pulsed Doppler showed clear elevation after starting the MTX chemotherapy. That may show the shrinkage of tumor mass caused by the chemotherapy. A non-sensitive trophoblastic tumor.e.g. invasive mole, did not show the elevation of RI and PI by the chemotherapy.

Prophylactic chemotherapy to prevent postmolar choriocarcinoma was tried in a controlled study in Kyushu University by us, looking the therapeutic effect of MTX on choriocarcinoma in 1968 [2]. Postmolar women were divided in two groups, who received orally 10 mg MTX for a week in the chemotherapy group, and the other received no chemotherapy. Since the chemotherapy was prolonged until the disappearance of urinary HCG, two persistent trophoblastic disease patients after complete mole received MTX for more than 200 mg in total. In the results, no choriocarcinoma developed in the chemotherapy group, while some choriocarcinoma developed in non-chemotherapy group with significant difference. Afterwards, choriocarcinoma was very rare in Japan.

We, medical staffs, will be very happy, if the primary chemotherapy and prophylactic chemotherapy are successful in the other malignancy as has done in choriocarcinoma.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11586
  • [From(publication date):
    August-2014 - Dec 11, 2017]
  • Breakdown by view type
  • HTML page views : 7806
  • PDF downloads : 3780
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version